Pliant and Acelyrin adopt poison pill measures to counter activist investor Kevin Tang's stock accumulation, aiming to ...

The move by Acelyrin’s board comes as the venture capital firm has taken larger and larger stakes in the company in an attempt to disrupt a merger with Alumis.

Acelyrin (NASDAQ:SLRN) announced Thursday a decision to adopt a limited-duration stockholder rights plan, also known as a poison pill, after Tang Capital Partners rapidly accumulated 8.8% of the ...

Both Pliant and Acelyrin have implemented their own “poison pill” plans. The rule changes mean that if a single investor secures 10% or more of either company’s stock, it will trigger ...

Acelyrin said Tang Capital held 8.8% of its outstanding common stock. Tang Capital didn't immediately respond to a request for comment issued through LinkedIn. Poison pills, also called ...

Drug development company Acelyrin Inc. recently saw a modest increase in its stock price after announcing the adoption of a ...

Today, a brief rundown of news involving Martin Makary, as well as updates from Pliant Therapeutics, Acelyrin and Sutro Biopharma that you may have missed. Over the past 10 years, PD1-blocking ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter.